TipRanks: Robert Burns Raises ArriVent Price Target to $47, Maintains Buy on Firmonertinib Late‑Stage Upside
- #news
- #headline
TipRanks: Robert Burns Raises ArriVent Price Target to $47, Maintains Buy on Firmonertinib Late‑Stage Upside
Captured 2026-08-20 from TipRanks. The archived copy is preserved so this citation survives link rot.